Ngm Biopharmaceuticals Stock Shares Owned By Institutions
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
NGM Biopharmaceuticals Company Shares Owned By Institutions Analysis
NGM Biopharmaceutica's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current NGM Biopharmaceutica Shares Owned By Institutions | 54.16 % |
Most of NGM Biopharmaceutica's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 54% of NGM Biopharmaceuticals are shares owned by institutions. This is 21.33% higher than that of the Pharmaceuticals sector and 14.02% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 38.13% lower than that of the firm.
NGM Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.NGM Biopharmaceutica is currently under evaluation in shares owned by institutions category among its peers.
NGM Fundamentals
Return On Equity | -0.7 | |||
Return On Asset | -0.38 | |||
Operating Margin | (179.78) % | |||
Current Valuation | (36.13 M) | |||
Shares Outstanding | 83.46 M | |||
Shares Owned By Insiders | 21.08 % | |||
Shares Owned By Institutions | 54.16 % | |||
Number Of Shares Shorted | 1.68 M | |||
Price To Earning | (21.12) X | |||
Price To Book | 0.86 X | |||
Price To Sales | 29.10 X | |||
Revenue | 4.42 M | |||
Gross Profit | (125.73 M) | |||
EBITDA | (144.33 M) | |||
Net Income | (142.38 M) | |||
Cash And Equivalents | 297.81 M | |||
Cash Per Share | 3.71 X | |||
Total Debt | 5.38 M | |||
Debt To Equity | 0.03 % | |||
Current Ratio | 7.49 X | |||
Book Value Per Share | 1.79 X | |||
Cash Flow From Operations | (132.2 M) | |||
Short Ratio | 1.26 X | |||
Earnings Per Share | (1.73) X | |||
Target Price | 1.66 | |||
Number Of Employees | 138 | |||
Beta | 1.26 | |||
Market Capitalization | 128.53 M | |||
Total Asset | 168.87 M | |||
Retained Earnings | (724.01 M) | |||
Working Capital | 136.36 M | |||
Current Asset | 330.81 M | |||
Current Liabilities | 43.69 M | |||
Net Asset | 168.87 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Bonds Directory Find actively traded corporate debentures issued by US companies |